Medical Device Companies: Consideration for Consignment Inventory and Related Sales Process

February 15, 2022

Many medical device companies have chosen to deploy a consignment inventory and sales approach for their related products. In this video, you’ll learn about the advantages and disadvantages of this strategy for both the company and third parties, as well as best practices to consider.


Transcript

Eli Silverman:

Many companies have chosen to deploy a consignment inventory and sales approach for their related medical devices equipment. This strategy has several advantages and potential disadvantages to the company, but prior to discussing these items, let's first discuss the background surrounding consignment inventory.

Consignment inventory is a supply chain management strategy in which the company ships product to a doctor, doctor's office, hospital, et cetera. The doctor's office or hospital will hold onto the company's products in their location until the goods are purchased by the end user or customer. For example, the company may ship spinal implants, screws, et cetera, to a hospital. The hospital will stock these items and they will be used in surgeries on an as-needed basis.

Advantages of this model for the company include the following. Greater overall visibility of the product especially in new markets and locations, reduce inventory holding costs as items are held by the third party, doctor or hospital, instead of the company, the company relies on the doctor or hospital for the sales channel, market proof for new and unproven products to test sales activity prior to large production loans, and build brand reputation and overall recognition.

Disadvantages of this model for the company include, revenue is not recognized and payments are received from a third party after inventory is sold to the end user and not when they're shipped to the third party. For example, the company will recognize revenue when the survey was performed and its product was used, then would receive payments after that time. The company will have investment for shipping costs of the new inventory to the various consigned locations. As the company still owns the inventory, any damage to the products will still be borne by the company versus the third party, i.e, the doctor's office or hospital. Potential lack of visibility in the third party's operations may lead to inadequate or lack of controls around the inventory.

Advantages of this model to the third party include, wider range of being displayed can increase traffic and related volumes, third party only needs to pay the company upon sale of the consigned goods, third party is not responsible for producing the inventory which are ultimately sold. And disadvantages of this model for the third party include, storage costs for consigned goods, particularly if this takes a long time to sell through, and potentially difficulty in segregating its own inventory versus consigned inventory.

In order for the consigned inventory and sales to be successful for all parties in these arrangements, it is important to develop strong relationships, communication, and coordination for all parties involved. Best practices include laying out all applicable terms in a contract for each party's responsibilities, using technology to track inventory levels and sales fulfillment, work with the company sales and marketing group internally, and with respective third parties to ensure communication check-ins to determine sales movement in a timely manner, periodic reconciliations of inventory levels between parties, periodic physical inventory accounts performed by a company at all consigned locations.

Overall, this is a good way to grow the overall geographic footprint and related sales base. It is critical the company set up procedures and controls to ensure that there is coordination in tracking inventory levels and related movement are done to ensure accurate overall report. Feel free to reach out if you have any questions.

About Eli Silverman

Eli Silverman is a Senior Audit Manager in firm’s Technology Group with over 5 years of experience


More in This Series

Cybersecurity Risks and Solutions for Life Sciences Startups

Cybersecurity poses a significant risk to life sciences startups that handle personal identifiable information. In this video, you’ll learn about the risks facing your business and how you can protect your clients and systems.

When Do I Need to Get an IRC Sec. 409A Valuation for My Stock Options or Stock Grants?

A 409A valuation is used by private companies to assess the fair market value of their stock. In this video, you’ll learn when a 409A valuation is necessary, the length of time in which it is valid, and which events trigger the need for an update

Capital Raising: What Are My Options—and How Do I Approach Investors?

In this video, you’ll learn about various options for raising capital, tips for creating your potential investor list, and how to approach investors.

What Technology and Life Sciences Companies Need to Know about being Acquired by a SPAC

Becoming a public company through an acquisition by a SPAC is an alternative to the traditional initial public offering (IPO). In this video, you’ll learn some key considerations that a technology or life sciences company should keep in mind before being acquired by a SPAC.

Going Global: How to Report Your Foreign Operations for Tax Purposes

In this video, we’ll examine why reporting on foreign operations for tax purposes is an important matter for technology and life sciences start-ups doing business abroad.

What Tax Considerations Does My IPO Trigger?

Is your company preparing for (or have you recently had) an IPO? In this video, you’ll learn about the impact that an ownership change under IRC Sec. 382 can have on the utilization of net operating loss (NOL) carryovers and other factors that can influence your tax burden.

What Technology and Life Sciences Companies Need to Know About Transfer Pricing—from Start-ups to Large MNEs

In this video, you will learn why transfer pricing is an important focus point for many multinational enterprises in the technology and life science industry.

Capital Raising: Are Financial Instruments Classified as Liabilities or Equity?

In this video, you'll learn about the different accounting ramifications for financial instruments issued to investors by start-ups and why it’s important to properly structure financial instruments upfront for accounting purposes.

Financing for Entrepreneurs: What Are Issuance Costs?

In this video, you’ll learn about “issuance costs” and how to properly account for them based on the type of funding that was raised.

Does My Start-up Need an Advisory Board?

In this video, you'll examine the ways how an advisory board differs from a board of directors; why you might consider forming an advisory board; how you can attract and retain advisory board members; and how you can enhance the effectiveness of the advisory board for your start-up.

What Technology and Life Sciences Companies Need to Know About SOC 1 Reports

Brenda DeSaro explains what a SOC 1 Report is, discusses why companies need to be concerned about these reports even though they likely outsource this work to third-party providers, and outlines a best practices approach.

Entrepreneurship: Behind the Numbers

John Pennett talks about the ingredients for successful entrepreneurship—from early to late-stage enterprises—with “Behind the Numbers” host and senior director at CFGI.